Cetuximab after immunotherapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies whether giving cetuximab after prior immunotherapy can help people with head and neck squamous cell cancer shrink tumors or slow their growth. You may be eligible if you’ve already had a PD-1–based immunotherapy treatment, and you meet health and safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed head and neck squamous cell cancer based on biopsy or cell testing.
- Your scans show at least one measurable tumor that can be tracked during the study.
- You previously received immunotherapy that targets PD-1 (with or without chemotherapy).
- You’re age 18 or older and can follow the study plan and sign consent.
- Your overall health is good enough (performance status 0–2) as judged by the study team.
- You have not had cetuximab before, and you have not had medicines that directly target the EGFR pathway in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
This study tests whether giving a combination of immunotherapy (camrelizumab) with either an EGFR antibody or chemotherapy before and after surgery can help treat locally advanced head and neck cancer. It aims to see if this approach improves outcomes compared to standard care.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a drug called anti-PD-1 (an immunotherapy that helps your immune system attack cancer) for people whose head and neck cancer has returned or spread but can still be removed with surgery. The goal is to see if this treatment helps control the cancer better.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.